Dietary acrylamide and incident osteoporotic fractures: an 8‑year prospective cohort study

Nicola Veronese*, Francesco Bolzetta , Chiara Cacco , Alberto Cester , Lee Smith, Jacopo Demurtas, Cyrus Cooper, Maria Gabriella Caruso , Maria Notarnicola , Stefania Maggi, Mario Barbagallo, Mike Trott, Ligia Dominguez

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Downloads (Pure)


Background: Acrylamide, a component of fried foods, has been associated with several negative health outcomes. However, the relationship between dietary acrylamide and osteoporotic fractures has been explored by a few cross-sectional studies. 

Aims: To investigate if dietary acrylamide is associated with the onset of fractures in North American participants at high risk/having knee osteoarthritis (OA), over 8 years of follow-up. 

Methods: A Cox’s regression analysis, adjusted for baseline confounders was run and the data were reported as hazard ratios (HRs) and 95% confidence intervals (CIs). Dietary acrylamide intake was assessed at the baseline using a food frequency questionnaire and categorized in tertiles (T), whilst fractures’ history was recorded using self-reported information. 

Results: Altogether, 4,436 participants were included. Compared to participants with lower acrylamide intake (T1; < 3,313 μg), those with a higher acrylamide intake (T3; > 10,180 μg) reported a significantly higher risk of any fracture (HR = 1.37; 95% CI 1.12–1.68; p for trend = 0.009), forearm (HR = 1.73; 95% CI 1.09–2.77; p for trend = 0.04), spine (HR = 2.21; 95% CI 1.14–4.31; p for trend = 0.04), and hip fracture (HR = 4.09; 95% CI 1.29–12.96; p for trend = 0.046).

Conclusions: Our study is the first to report that high dietary acrylamide may be associated with an increased risk of osteoporotic fractures.

Original languageEnglish
Pages (from-to)2441–2448
JournalAging Clinical and Experimental Research
Early online date13 Aug 2022
Publication statusPublished - Oct 2022
Externally publishedYes

Bibliographical note

Funding Information:
Open access funding provided by Università degli Studi di Palermo within the CRUI-CARE Agreement. Publication costs are supported by the FFR2021 fund of the University of Palermo assigned to Prof. Mario Barbagallo and Nicola Veronese. The OAI is a public–private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners.

Publisher Copyright:
© 2022, The Author(s).


  • Acrylamide
  • Fracture
  • Osteoarthritis initiative
  • Osteoporosis

ASJC Scopus subject areas

  • Ageing
  • Geriatrics and Gerontology


Dive into the research topics of 'Dietary acrylamide and incident osteoporotic fractures: an 8‑year prospective cohort study'. Together they form a unique fingerprint.

Cite this